Immunotherapy Drugs Market Share, Growth, Opportunities 2031
Immunotherapy Drugs Market Share, Growth, Opportunities 2031
Segments - Immunotherapy Drugs Market by Product Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons, Vaccines, and Interleukins), Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others), End-user (Hospitals, Specialty Clinics, and Research Institutes), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5361
| 4.6 Rating
| 64 Reviews
| 236 Pages
| Format :
Report Description
The global immunotherapy drugs market size was USD 202.5 Bn in 2022 and is likely to reach USD 425.5 Bn by 2031, expanding at a CAGR of 8.7% during 2023–2031. The market is propelled by the rising prevalence of chronic diseases such as cancer, autoimmune diseases, and kidney dysfunction along with the growing popularity of immunotherapy drugs.
Immunotherapy drugs are developed to stimulate the natural defense mechanism of the human immune system to treat various types of health complications such as autoimmune diseases, cancer, and infectious diseases. The human immune system comprises a network of cells, proteins, and organs that protects the human mechanism against infections by identifying and neutralizing disease-causing micro-organisms.
Immunotherapy drugs are made up of substances tested and approved by regulatory bodies that empower the immune system by harnessing the defense mechanism of the human body. Immunotherapy drugs improve the immune system of the human body by improving the cellular mechanism. The various types of immunotherapy drugs include chimeric antigen receptor (CAR) T-cell therapy, checkpoint inhibitors, cytokines, cancer vaccines, immunomodulators, oncolytic viruses, and monoclonal antibodies.
The market report finds that the COVID-19 pandemic positively affected the market due to the rising demand for immunotherapy drugs for the treatment of COVID-19. The preference for these drugs grew owing to their efficacy and safety.
The COVID-19 pandemic accelerated drug and vaccine development programs to curb the spread of the virus and contain the damage globally. The researchers emphasized finding the cure for COVID-19 by using immunotherapy drugs by enhancing the natural defense mechanism of the human body.
Immunotherapy Drugs Market Dynamics
Major Drivers
Rising prevalence of chronic diseases such as autoimmune diseases and cancer is expected to drive the market. According to data published by Pan American Health Organization on World Cancer Day (on 4th February 2023), the global cancer burden is likely to increase to 30 million new cancer cases by 2040. The cancer burden is likely to rise by approximately 60% over the next two decades.
The immunotherapy drugs such as checkpoint inhibitors, chimeric antigen receptor (CAR) T-cells, cytokines, and immunomodulators are used to treat a variety of cancers by activating the immune system to treat cancer. For instance, CAR T-cell therapy uses T-cells extracted from a patient’s blood. The T-cells are exposed to a variety of special viruses that enables T-cells to limit the growth of cancer-causing cells during cancer immunotherapy treatment.
Growing popularity of immunotherapy drugs due to the enhanced safety and efficacy of the treatments is anticipated to propel the market. Immunotherapy works on the principle of improving the natural defense mechanism of the human body thus it has minimum complications.
For example, some immunotherapy drugs such as CAR T-cells and inhibitors work on neutralizing the specific proteins present on the surface of the cancer cells in the human mechanism that prevents the T-cells from identifying and eliminating the cancerous cells. Such mechanisms enhance the natural defense of the human body thus it does not aggregate harmful chemical reactions.
Existing Restraints
The high cost of immunotherapy drugs is likely to impede the market. A 2020 estimate quoted in Statnews, an American health-oriented news website states that the average annual cost of healthcare and drugs was more than USD 42,000 while 30% of Americans with cancer face difficulty in paying the bills. More than 40% of patients had to shell out their life savings in the first two years of the cancer treatment.
Emerging Opportunities
Rising demand for biosimilars and monoclonal antibodies and a high approval rate for immunotherapy drugs are likely to create significant opportunities for the market. Biosimilars are complex biotherapeutic proteins that can be easily administered to the patient.
They are complex, large proteins used to detect and neutralize external attacks from viruses and bacteria. Biosimilars are expected to reduce treatment costs and improve treatment access associated with cancer treatment.
Scope of the Immunotherapy Drugs Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Immunotherapy Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Product Type (Monoclonal Antibodies, Checkpoint Inhibitors, Interferons, Vaccines, and Interleukins), Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others), and End-user (Hospitals, Specialty Clinics, and Research Institutes) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Novartis AG; AstraZeneca; F. Hoffmann-La Roche Ltd; Abbott; PerkinElmer Inc.; QIAGEN; Sanofi; Pfizer Inc.; AbbVie Inc.; GSK plc.; and Bayer AG |
Immunotherapy Drugs Market Segment Insights
Based on product type, the immunotherapy drugs market is divided into monoclonal antibodies, checkpoint inhibitors, interferons, vaccines, and interleukins. The monoclonal antibodies segment is expected to expand at a major growth rate during the projection period owing to the enhanced efficacy and safety of monoclonal antibodies in the treatment of cancer and other chronic diseases. The rising popularity of targeted therapies that comprise antibodies to target specific antigens for curing diseases is likely to propel the market.
The checkpoint inhibitors segment is anticipated to hold a key share of the market in the coming years due to the efficacy of checkpoint inhibitors in the treatment of cancers such as lung and melanoma skin cancer. Checkpoint inhibitors are a type of targeted treatment that block certain types of proteins that prevent the immune system from attacking the cancer cells.
On the basis of application, the global market is segregated into cancer, autoimmune diseases, infectious diseases, and others. The cancer segment is projected to register a considerable CAGR during the forecast period due to the high efficacy rates and easy administration of immunotherapy drugs. Immunotherapy drugs either stop or slow down the progression of cancer cells in the human mechanism. For example, checkpoint inhibitors break the connection between the checkpoint and other proteins. When the connection breaks down, the T-cells in the body start attacking cancerous cells.
The autoimmune diseases segment is expected to hold a substantial share of the market in the forecast period due to the rising prevalence of autoimmune diseases and the growing adaptability of immunotherapy drugs to treat autoimmune diseases. Immunotherapy drugs help T-cells to identify and destroy the autoimmune disease-causing cells.
Based on end-user, the immunotherapy drugs market is segmented into hospitals, specialty clinics, and research institutes. The hospitals segment is expected to register a robust growth rate during the forecast period owing to the over-the-counter availability of immunotherapy drugs and follow-up consultation provided at the hospitals. Chronic patients need to visit the hospitals for regular checkups and diagnoses. Doctors prescribe them the immunotherapy drugs as per the requirement after a thorough diagnosis on the hospital premises.
The specialty clinics segment is expected to hold a substantial share of the market in the forecast period due to the easy accessibility and affordability provided by the specialty clinics. Specialty clinics are highly accessible as they are strategically located to provide healthcare services to patients at competitive and reasonable prices.
Regional Outlook
In terms of region, the global immunotherapy drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period owing to the rising prevalence of cancer and autoimmune diseases and the availability of novel immunotherapy drugs in the region. The government initiatives to promote immunotherapy drugs have created a conducive atmosphere for the growth of the market by providing reimbursement facilities to the patients who avail the immunotherapy treatments.
The market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to the rising prevalence of cancer and autoimmune diseases in the region and government initiatives to promote immunotherapy drugs as an effective line of treatment in emerging economies such as India and China. The research organizations are exploring various lines of treatments with safe and effective results. The rising cases of cancer and autoimmune diseases have prompted healthcare professionals to choose immunotherapy drugs as it has high efficacy rates and can be easily administered.
Segments
The immunotherapy drugs market has been segmented on the basis of
Product Type
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Interferons
- Vaccines
- Interleukins
Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
End-user
- Hospitals
- Specialty Clinics
- Research Institutes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Novartis AG
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Abbott
- PerkinElmer Inc.
- QIAGEN
- Sanofi
- Pfizer Inc.
- AbbVie Inc.
- GSK plc.
- Bayer AG
Competitive Landscape
Key players competing in the global immunotherapy drugs market are Novartis AG; AstraZeneca; F. Hoffmann-La Roche Ltd; Abbott; PerkinElmer Inc.; QIAGEN; Sanofi; Pfizer Inc.; AbbVie Inc.; GSK plc.; and Bayer AG
These companies in the immunotherapy drugs domain adopted development strategies including the launch of novel therapies, the development of research facilities with the help of mergers, acquisitions, partnerships, and collaboration, with the potential of partners to offer diversified products and services to consumers worldwide. For instance,
- On November 23, 2022, Bayer AG, one of the major manufacturers of immunotherapy drugs, announced that it has collaborated with three companies namely GRO Biosciences, Mozart Therapeutics, and Deka Biosciences to offer advanced techniques of targeted immunotherapies for autoimmune diseases. Mozart Therapeutics is using CD8 T cells to target T-cells while Deka Biosciences is using Cytokines proteins to treat cancer. It is anticipated that almost 8% of the world’s population is suffering from autoimmune diseases. The treatments developed by Bayer are likely to benefit the majority of people suffering from autoimmune diseases.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Immunotherapy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immunotherapy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immunotherapy Drugs Market - Supply Chain
4.5. Global Immunotherapy Drugs Market Forecast
4.5.1. Immunotherapy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immunotherapy Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Immunotherapy Drugs Market Absolute $ Opportunity
5. Global Immunotherapy Drugs Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Immunotherapy Drugs Market Size and Volume Forecast by Applications
5.3.1. Cancer
5.3.2. Autoimmune Diseases
5.3.3. Infectious Diseases
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Immunotherapy Drugs Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Immunotherapy Drugs Market Size and Volume Forecast by End Users
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Research Institutes
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Immunotherapy Drugs Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Immunotherapy Drugs Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Immunotherapy Drugs Demand Share Forecast, 2019-2026
8. North America Immunotherapy Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Immunotherapy Drugs Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Immunotherapy Drugs Market Size and Volume Forecast by Applications
8.4.1. Cancer
8.4.2. Autoimmune Diseases
8.4.3. Infectious Diseases
8.4.4. Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America Immunotherapy Drugs Market Size and Volume Forecast by End Users
8.7.1. Hospitals
8.7.2. Specialty Clinics
8.7.3. Research Institutes
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Immunotherapy Drugs Demand Share Forecast, 2019-2026
9. Latin America Immunotherapy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Immunotherapy Drugs Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Immunotherapy Drugs Market Size and Volume Forecast by Applications
9.4.1. Cancer
9.4.2. Autoimmune Diseases
9.4.3. Infectious Diseases
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America Immunotherapy Drugs Market Size and Volume Forecast by End Users
9.7.1. Hospitals
9.7.2. Specialty Clinics
9.7.3. Research Institutes
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Immunotherapy Drugs Demand Share Forecast, 2019-2026
10. Europe Immunotherapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Immunotherapy Drugs Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Immunotherapy Drugs Market Size and Volume Forecast by Applications
10.4.1. Cancer
10.4.2. Autoimmune Diseases
10.4.3. Infectious Diseases
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe Immunotherapy Drugs Market Size and Volume Forecast by End Users
10.7.1. Hospitals
10.7.2. Specialty Clinics
10.7.3. Research Institutes
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Immunotherapy Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by Applications
11.4.1. Cancer
11.4.2. Autoimmune Diseases
11.4.3. Infectious Diseases
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by End Users
11.7.1. Hospitals
11.7.2. Specialty Clinics
11.7.3. Research Institutes
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Immunotherapy Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by Applications
12.4.1. Cancer
12.4.2. Autoimmune Diseases
12.4.3. Infectious Diseases
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by End Users
12.7.1. Hospitals
12.7.2. Specialty Clinics
12.7.3. Research Institutes
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Immunotherapy Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Immunotherapy Drugs Market: Market Share Analysis
13.2. Immunotherapy Drugs Distributors and Customers
13.3. Immunotherapy Drugs Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Novartis AG
13.4.2. AstraZeneca
13.4.3. F. Hoffmann-La Roche Ltd
13.4.4. Abbott
13.4.5. PerkinElmer Inc.
13.4.6. QIAGEN
13.4.7. Sanofi
13.4.8. Pfizer Inc.
13.4.9. AbbVie Inc.
13.4.10. GSK plc.
13.4.11. Bayer AG
Methodology
Related Reports
Some other reports from this category!
Our Clients
